% | $
Quotes you view appear here for quick access.

GlaxoSmithKline plc Message Board

  • ihavethelongestaliasyoueversaw ihavethelongestaliasyoueversaw Feb 15, 2013 7:04 AM Flag

    Will GSK's buyout of PATH (Nupathe, Inc.) migrane patch and delivery technology benefit GSK?

    It is somewhat obvious that GSK may purchase PATH for its FDA newly approved migrane patch and patented delivery technology but what price can they affors to pay without hurting their present bottom line.

44.3598-0.0502(-0.11%)1:18 PMEDT